Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases

被引:49
作者
Handelsman, Yehuda [1 ]
Butler, Javed [2 ,3 ]
Bakris, George L. [4 ]
DeFronzo, Ralph A. [5 ]
Fonarow, Gregg C. [6 ]
Green, Jennifer B. [7 ,8 ]
Grunberger, George [9 ,10 ]
Januzzi, James L., Jr. [11 ]
Klein, Samuel [12 ,13 ]
Kushner, Pamela R. [14 ]
McGuire, Darren K. [15 ,16 ]
Michos, Erin D. [17 ]
Morales, Javier [18 ,19 ]
Pratley, Richard E. [20 ]
Weir, Matthew R. [21 ]
Wright, Eugene [22 ]
Fonseca, Vivian A. [23 ]
机构
[1] Metab Inst Amer, Tarzana, CA 91356 USA
[2] Baylor Scott & White Hlth, Baylor Scott & White Res Inst, Dallas, TX USA
[3] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[4] Univ Chicago, Pritzker Sch Med, Amer Heart Assoc, Comprehens Hypertens Ctr, Chicago, IL 60637 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, Texas Diabet Inst, San Antonio, TX 78229 USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Div Cardiol,UCLA Preventat Cardiol Program, Ahmanson UCLA Cardiomyopathy Ctr,Ronald Reagan UC, Los Angeles, CA 90095 USA
[7] Duke Univ, Med Ctr, Div Endocrinol, Durham, NC USA
[8] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[9] Wayne State Univ, Sch Med, Dept Internal Med,Oakland Univ,William Beaumont S, Grunberger Diabet Inst Internal Med & Mol Med & G, Bloomfield Hills, MI USA
[10] Charles Univ Prague, Fac Med 1, Dept Internal Med, Prague, Czech Republic
[11] Harvard Med Sch, Massachusetts Gen Hosp, Cardiometabol Trials, Cardiol Div,Baim Inst, Boston, MA 02115 USA
[12] Washington Univ, Sch Med, St Louis, MO USA
[13] Sansum Diabet Res Inst, Santa Barbara, CA USA
[14] Univ Calif Med Ctr, Kushner Wellness Ctr, Long Beach, CA USA
[15] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[16] Parkland Hlth & Hosp Syst, Dallas, TX USA
[17] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA
[18] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, Hempstead, NY USA
[19] Adv Internal Med Grp PC, E Hills, NY USA
[20] AdventHlth Translat Res Inst, Orlando, FL USA
[21] Univ Maryland, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21201 USA
[22] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[23] Tulane Univ, Hlth Sci Ctr, Endocrinol Sect, New Orleans, LA 70118 USA
关键词
Diabetes; Cardiovascular disease; Obesity; Heart failure; Chronic kidney disease; NAFLD; CLINICAL-PRACTICE GUIDELINES; CARDIOVASCULAR RISK-FACTORS; FATTY LIVER-DISEASE; CORONARY-ARTERY CALCIUM; LIFE-STYLE INTERVENTION; ASSOCIATION TASK-FORCE; AMERICAN ASSOCIATION; HEART-FAILURE; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE;
D O I
10.1016/j.jdiacomp.2022.108389
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence.
引用
收藏
页数:11
相关论文
共 140 条
[1]   Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial [J].
Abu Dayyeh, Barham K. ;
Bazerbachi, Fateh ;
Vargas, Eric J. ;
Sharaiha, Reem Z. ;
Thompson, Christopher C. ;
Thaemert, Bradley C. ;
Teixeira, Andre F. ;
Chapman, Christopher G. ;
Kumbhari, Vivek ;
Ujiki, Michael B. ;
Ahrens, Jeanette ;
Day, Courtney ;
Neto, Manoel Galvao ;
Zundel, Natan ;
Wilson, Erik B. .
LANCET, 2022, 400 (10350) :441-451
[2]   Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial [J].
Abu Dayyeh, Barham K. ;
Maselli, Daniel B. ;
Rapaka, Babusai ;
Lavin, Thomas ;
Noar, Mark ;
Hussan, Hisham ;
Chapman, Christopher G. ;
Popov, Violeta ;
Jirapinyo, Pichamol ;
Acosta, Andres ;
Vargas, Eric J. ;
Storm, Andrew C. ;
Bazerbachi, Fateh ;
Ryou, Marvin ;
French, Matthew ;
Noria, Sabrena ;
Molina, Daniel ;
Thompson, Christopher C. .
LANCET, 2021, 398 (10315) :1965-1973
[3]   Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [J].
Agarwal, Rajiv ;
Filippatos, Gerasimos ;
Pitt, Bertram ;
Anker, Stefan D. ;
Rossing, Peter ;
Joseph, Amer ;
Kolkhof, Peter ;
Nowack, Christina ;
Gebel, Martin ;
Ruilope, Luis M. ;
Bakris, George L. .
EUROPEAN HEART JOURNAL, 2022, 43 (06) :474-+
[4]   10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S144-S174
[5]   8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee* .
DIABETES CARE, 2022, 45 :S113-S124
[6]   9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S125-S143
[7]   3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S39-S45
[8]   7. Diabetes Technology: Standards of Medical Care in Diabetes-2022 [J].
不详 .
DIABETES CARE, 2022, 45 :S97-S112
[9]  
Amer Diabet Assoc Professional Pra, 2022, DIABETES CARE, V45, pS175, DOI [10.2337/dc22-S011, 10.2337/dc22-ad08a]
[10]  
[Anonymous], National Health Statistics Reports NHSR No. 158 ed, DOI DOI 10.15620/CDC:106273